9JK1
Crystal structure of CDK12/Cyclin K in complex with covalent inhibitor YJZ5118
これはPDB形式変換不可エントリーです。
9JK1 の概要
エントリーDOI | 10.2210/pdb9jk1/pdb |
分子名称 | Cyclin-dependent kinase 12, Cyclin-K, 1,2-ETHANEDIOL, ... (7 entities in total) |
機能のキーワード | kinase, covalent inhibitor, selective, transferase |
由来する生物種 | Homo sapiens (human) 詳細 |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 143760.22 |
構造登録者 | |
主引用文献 | Yang, J.,Chang, Y.,Zhou, K.,Huang, W.,Tien, J.C.,Zhang, P.,Liu, W.,Zhou, L.,Zhou, Y.,Ren, X.,Mannan, R.,Mahapatra, S.,Zhang, Y.,Hamadeh, R.,Ervine, G.,Wang, Z.,Wang, G.X.,Chinnaiyan, A.M.,Ding, K. Discovery of YJZ5118 : A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition. J.Med.Chem., 68:6718-6734, 2025 Cited by PubMed Abstract: Cyclin-dependent kinases 12 and 13 (CDK12/13) have emerged as promising therapeutic targets for castration-resistant prostate cancer (CRPC) and other human cancers. Despite the development of several CDK12/13 inhibitors, challenges remain in achieving an optimal balance of potency, selectivity and pharmacokinetic properties. Here, we report the discovery of , a novel, potent and highly selective covalent inhibitor of CDK12/13 with reasonable pharmacokinetic profiles. effectively inhibited CDK12 and CDK13 with IC values of 39.5 and 26.4 nM, respectively, while demonstrating high selectivity over other CDKs. Mass spectrometry analysis, cocrystal structure determination, and pulldown-proteomic experiments confirmed the compound's covalent binding mode with CDK12/13. Functionally, efficiently suppressed the transcription of DNA damage response genes, induced DNA damage, and triggered apoptosis. Moreover, the compound significantly inhibited the proliferation of multiple tumor cell lines, particularly prostate cancer cells. Notably, exhibited synergistic effects with Akt inhibitors both in vitro and in vivo. PubMed: 40080446DOI: 10.1021/acs.jmedchem.5c00127 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.72 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
